Quick Answer
AbCellera Biologics Inc. reported Total Revenue of $75.13 million for the year ending 2025.
- AbCellera Biologics Inc. showed an increase of +160.6% in Total Revenue from 2024 to 2025.
- This data is from AbCellera Biologics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $4.66 million | Q2 2020: $11.23 million | Q3 2020: $9.36 million | Q1 2021: $202.74 million | Q2 2021: $27.64 million | Q3 2021: $5.51 million | Q1 2022: $316.58 million | Q2 2022: $45.92 million | Q3 2022: $101.38 million | Q1 2023: $12.19 million | Q2 2023: $10.06 million | Q3 2023: $6.60 million | Q1 2024: $9.95 million | Q2 2024: $7.32 million | Q3 2024: $6.51 million | Q1 2025: $4.24 million | Q2 2025: $17.08 million | Q3 2025: $8.96 million.
- Over the full 7 years of available data (2019 to 2025), AbCellera Biologics Inc.'s Total Revenue has grown by 547.0%.
- Historical annual values: Fiscal year 2025: $75.13 million | Fiscal year 2024: $28.83 million | Fiscal year 2023: $38.03 million | Fiscal year 2022: $485.42 million | Fiscal year 2021: $375.20 million | Fiscal year 2020: $233.16 million | Fiscal year 2019: $11.61 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: